Antibiotic treatment of Stenotrophomonas maltophilia bacteraemia: does trimethoprim/sulfamethoxazole dose affect clinical outcomes?
Journal of Antimicrobial Chemotherapy · 03.06.2025 · 80 (6) · 1716-1725
DOI: 10.1093/jac/dkaf131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 24.04.2025. Verfasst von Wei-Ping Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, Taoyuan Armed Forces General Hospital, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Stenotrophomonas maltophilia, Trimethoprim, Sulfamethoxazole Drug Combination, Bacteremia, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Tri-Service General Hospital Penghu Branch, Tri-Service General Hospital, National Defense Medical Center.
Abstract (Originalsprache)
Objectives
The benefit of high-dose trimethoprim/sulfamethoxazole (trimethoprim component ≥ 8 mg/kg/day) treatment for Stenotrophomonas maltophilia infections remains unclear. We aimed to evaluate the effect of high-dose trimethoprim/sulfamethoxazole treatment on outcomes in patients with S. maltophilia bacteraemia. Patients and methods We conducted a single-centre retrospective cohort study (2004–23) that included patients treated with trimethoprim/sulfamethoxazole for monomicrobial S. maltophilia bacteraemia. The patients were categorized into two groups based on the trimethoprim/sulfamethoxazole dose: high-dose (trimethoprim component ≥ 8 mg/kg/day) and low-dose (trimethoprim component < 8 mg/kg/day) groups for comparison. The primary endpoint was 30-day mortality. Adverse drug events between groups were also compared. Multivariable logistic regression and inverse probability of treatment weighting (IPTW) analysis were performed.
Results
A total of 143 patients treated with trimethoprim/sulfamethoxazole for S. maltophilia bacteraemia were included: 41 (28.7%) received the high-dose regimen, and 102 (71.3%) received the low-dose regimen. There was no significant difference in 30-day mortality between the high- and low-dose group (39.0% versus 26.5%; P = 0.139). Multivariable regression revealed that high-dose trimethoprim/sulfamethoxazole therapy was not associated with mortality (adjusted OR 1.96, 95% CI 0.75–5.10; P = 0.167) after adjustment. The IPTW-adjusted regression yielded consistent results. More adverse drug events were reported in the high-dose group (31.7% versus 12.7%, P = 0.008).
Conclusions
High-dose trimethoprim/sulfamethoxazole for S. maltophilia bacteraemia was not associated with improved outcomes while more frequent adverse drug events were observed. The sample size and retrospective design limit the study’s conclusions. Future studies that address these limitations are needed to confirm the results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Internal Medicine, Taoyuan Armed Forces General Hospital, Taoyuan, Taiwan.
- Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Tri-Service General Hospital, National Defense Medical Centre, 7F, No. 325, Section 2, Cheng-Kung Road, Neihu District, Taipei 114, Taiwan.
- Division of Infectious Diseases, Department of Internal Medicine, Zuoying Armed Forces General Hospital, Kaohsiung, Taiwan.
- Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.
- Department of Pathology, Tri-Service General Hospital, National Defense Medical Centre, Taipei, Taiwan.
ORCID-Profile: Chien-Liang Chen
Förderung
- Tri-Service General Hospital Penghu Branch
- Tri-Service General Hospital
- National Defense Medical Center
- National Defense Medical Centre
Zitieren
APA
Chen, W. P., Chen, C. L., Siu, L. K., Chang, F. Y., Yu, C. M., Shang, H. S., Yang, Y. S., Lin, J. C., & Wang, C. H. (2025). Antibiotic treatment of Stenotrophomonas maltophilia bacteraemia: does trimethoprim/sulfamethoxazole dose affect clinical outcomes?. Journal of Antimicrobial Chemotherapy, 80(6), 1716-1725. https://doi.org/10.1093/jac/dkaf131
Vancouver
Chen WP, Chen CL, Siu LK, Chang FY, Yu CM, Shang HS, et al. Antibiotic treatment of Stenotrophomonas maltophilia bacteraemia: does trimethoprim/sulfamethoxazole dose affect clinical outcomes?. Journal of Antimicrobial Chemotherapy. 2025;80(6):1716-1725. doi:10.1093/jac/dkaf131
BibTeX
@article{Chen2025,
author = {Chen, Wei-Ping and Chen, Chien-Liang and Siu, L Kristopher and Chang, Feng-Yee and Yu, Ching-Mei and Shang, Hung-Sheng and Yang, Ya-Sung and Lin, Jung-Chung and Wang, Ching-Hsun},
title = {Antibiotic treatment of Stenotrophomonas maltophilia bacteraemia: does trimethoprim/sulfamethoxazole dose affect clinical outcomes?},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {6},
pages = {1716--1725},
doi = {10.1093/jac/dkaf131}
}
EUVIMED